10-05-2021, 04:12 PM
I was watching War Room Pandemic this morning and one of Steve Bannon’s guests was Sharri Markson, author of What Really Happened In Wuhan and an award-winning journalist from Australia. Her computer research team which helped her gather information for her book uncovered some new interesting information regarding what the CCP government was purchasing prior to the start of the “pandemic” in December 2019. It appears the Chinese government was purchasing a large amount of Coronavirus testing machines prior to the pandemic in July-August 2019.
What makes this even more interesting is the fact the Bill and Melinda Gates Foundation invested $55 million in BioNTech in the exact same time frame. Since that purchase, Gates has made a whopping $719 million profit! Coincidence? I’ll let the reader decide.
Sources
SEC
https://www.sec.gov/Archives/edgar/data/...504df1.htm
Sharri Markson Interview:
https://rumble.com/vnbutq-massive-buy-of...c-hit.html
Important Note: Here’s the key excerpt from the SEC link above as it’s a rather tedious read:
"Our investors currently include... the Bill & Melinda Gates Foundation."
"On August 30, 2019, we entered into a letter agreement and an investment agreement with the Bill & Melinda Gates Foundation, or BMGF, pursuant to which BMGF acquired 3,038,674 of our ordinary shares for $55 million at the price of our Series B financing."
First case of COVID-19 dates back to November 17, 2019 according to South China Morning Post and there are reports of a potential outbreak during the October 18-27, 2019 Military Games in Wuhan, China.
To summarize, Gates invested $55 million in BioNTech 1.5 - 2.5 months before the first COVID-19 cases.
October 1, 2021: BioNTech (BNTX) $254.79 per share
3,038,674 shares x $254.79 = $774,223,748.46
$774,223,748.46 - $55,000,000 = $719,223,748.46
Since August 30, 2019, Gates made $719 million in profit on his $55 million BioNTech investment.
"We are a clinical-stage biopharmaceutical company with no pharmaceutical products approved for commercial sale."
"No mRNA immunotherapy has been approved, and none may ever be approved, in this new potential category of therapeutics. mRNA drug development has substantial clinical development and regulatory risks due to the novel and unprecedented nature of this new category of therapeutics."
"To our knowledge, there is no current precedent for an mRNA-based immunotherapy such as the type we are developing being approved for sale by the FDA, European Commission or any other regulatory agency elsewhere in the world."
What makes this even more interesting is the fact the Bill and Melinda Gates Foundation invested $55 million in BioNTech in the exact same time frame. Since that purchase, Gates has made a whopping $719 million profit! Coincidence? I’ll let the reader decide.
Sources
SEC
https://www.sec.gov/Archives/edgar/data/...504df1.htm
Sharri Markson Interview:
https://rumble.com/vnbutq-massive-buy-of...c-hit.html
Important Note: Here’s the key excerpt from the SEC link above as it’s a rather tedious read:
"Our investors currently include... the Bill & Melinda Gates Foundation."
"On August 30, 2019, we entered into a letter agreement and an investment agreement with the Bill & Melinda Gates Foundation, or BMGF, pursuant to which BMGF acquired 3,038,674 of our ordinary shares for $55 million at the price of our Series B financing."
First case of COVID-19 dates back to November 17, 2019 according to South China Morning Post and there are reports of a potential outbreak during the October 18-27, 2019 Military Games in Wuhan, China.
To summarize, Gates invested $55 million in BioNTech 1.5 - 2.5 months before the first COVID-19 cases.
October 1, 2021: BioNTech (BNTX) $254.79 per share
3,038,674 shares x $254.79 = $774,223,748.46
$774,223,748.46 - $55,000,000 = $719,223,748.46
Since August 30, 2019, Gates made $719 million in profit on his $55 million BioNTech investment.
"We are a clinical-stage biopharmaceutical company with no pharmaceutical products approved for commercial sale."
"No mRNA immunotherapy has been approved, and none may ever be approved, in this new potential category of therapeutics. mRNA drug development has substantial clinical development and regulatory risks due to the novel and unprecedented nature of this new category of therapeutics."
"To our knowledge, there is no current precedent for an mRNA-based immunotherapy such as the type we are developing being approved for sale by the FDA, European Commission or any other regulatory agency elsewhere in the world."
